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Introduction
Within the large family of G protein-coupled receptors 
(GPCR), the adrenergic receptors (ARs) mediate the func-
tional effects of catecholamines, like epinephrine and 
norepinephrine. The AR family includes nine different 
gene products, three β (β1, β2, β3), three α1 (α1a, α1b, and 
α1d), and three α2 (α2A, α2B, and α2C) receptor subtypes.
The α1-AR subtypes are expressed in various organs, 
including brain, heart, blood vessels, liver, kidney, pros-
tate, and spleen, in which they mediate a variety of func-
tional effects such as modulation of neurotransmission, 
vasoconstriction,  cardiac  inotropy,  and  chronotropy, 
regulation of metabolism (reviewed in ref. 1). Activation 
of the three α1-AR subtypes causes polyphosphoinositide 
hydrolysis catalyzed by phospholipase C (PLC) via per-
tussis toxin-insensitive G proteins in most tissues where 
this effect has been examined (1).
Radioligand  binding  studies  in  rat  tissues  initially 
demonstrated two classes of α1-AR binding sites, “A” and 
“B” with high and low affinity for the α1-AR   antagonists 
WB4101 and phentolamine, respectively. The first α1-AR 
cloned,  was  unequivocally  assigned  to  the  pharma-
cological  α1B  subtype  and  hence  named  α1b-AR.  The 
pharmacological α1A subtype, today identified as α1a-AR, 
was  initially  cloned  from  a  bovine  brain  library  and 
inappropriately named α1C-AR or α1A/C-AR. Finally, the 
cloned α1d-AR (initially named α1A-AR or α1A/D-AR) was a 
novel receptor subtype not clearly identified by previous 
  pharmacological studies (reviewed in ref. 2,3).
Studies  aiming  to  assess  the  specific  functional 
responses  mediated  by  distinct  α1-AR  subtypes  have 
been hampered by the fact that the subtype-selective 
drugs are only moderately selective. Recently, studies 
on genetically modified mice lacking or overexpressing 
one or more α1-AR subtypes have provided some impor-
tant insight into the functional roles played by distinct 
receptors. However, our understanding on the functional 
implications  of  α1-AR  heterogeneity  in  physiological 
  systems is still quite limited.
Extensive mutational analysis performed by our group 
and other investigators helped to identify the structural 
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determinants of the α1-AR subtypes involved in each of 
the three main “classical” functional properties of GPCRs: 
(i) ligand-binding; (ii) receptor activation and coupling to 
G protein; and (iii) desensitization. These findings have 
been reviewed elsewhere (4,5). Beyond these “classical” 
features, a number of novel functional paradigms have 
been recently described for GPCRs including receptor 
constitutive activity (6), oligomerization (7) and interac-
tion with a variety of signaling proteins (8). These func-
tional features imply a growing complexity of signaling 
and regulation of the α1-AR subtypes which might repre-
sent the mechanistic basis of their functional specificity 
in various tissues.
The aim of this review is to summarize our current 
knowledge on some recently identified functional para-
digms and signaling networks that might help to elucidate 
the functional diversity of the α1-AR subtypes in various 
organs.
Constitutive activity of the α1-AR subtypes
For both the α1a and α1b-AR mutation-induced and spon-
taneous constitutive activity have been reported (9,10). 
Interestingly, most of the known α-blockers behave as 
inverse agonists both at the wild type and constitutively 
actve  mutants  of  the  two  receptors  (10).  Studies  on 
constitutively  activating  mutations  of  the  α1b-AR  pro-
vided  important  insight  into  the  potential  molecular 
mechanisms of GPCR activation (11). In particular, they 
highlighted the highly conserved E/DRY sequence at the 
cytoslic end of helix 3 as an important switch of receptor 
activation.
Interestingly, activating mutations which perturb the 
helix 3/helix 6 packing of the receptor have been found 
in both the α1a and α1b-AR subtypes suggesting common 
mechanisms of receptor activation (12). These include: 
(i) mutations of A293(6.34) and of A271(6.34) in the cytosolic 
extension of helix 6 in the α1b-AR and α1a-AR, respec-
tively (9,10); (ii) mutations of D142(3.49) and D123(3.49) of 
the E/DRY motif in the α1b-AR and α1a-AR, respectively 
(10,11).
However,  some  differences  in  the  activation  prop-
erties can be observed between the α1a and α1b-AR in 
recombinant systems measuring the inositol phosphate 
response. The agonist-independent activity of both the 
wild type α1b-AR and its constitutively active mutants was 
significantly higher than that of the wild type α1a-AR or 
its mutant. In contrast, the epinephrine-induced inositol 
phosphate accumulation above basal at the α1a-AR was 
significantly higher than that at the α1b-AR or its consti-
tutively active mutants expressed at comparable levels 
(10,13). This suggests that in recombinant systems the 
agonist-occupied α1a-AR has greater efficacy in activat-
ing  PLC  than  the  α1b-AR  whereas  its  spontaneous  or 
mutation-induced isomerization toward the active states 
is lower. Only one study reported the opposite showing 
that in rat neonatal cardiomyocytes a different constitu-
tively active mutant of the α1a-AR displayed higher basal 
activity than the analogous mutant of the α1b-AR (14). This 
finding is intriguing and should be further explored.
The  properties  of  the  α1d-AR  subtype  have  been 
investigated very little because its expression as well 
as  the  agonist-induced  inositol  phosphate  response 
mediated by this receptor were often found to be much 
smaller than those of the other two subtypes (15,16). 
Constitutively activating mutations of the α1d-AR have 
not been reported so far. However, an interesting study 
reported that the α1d-AR expressed in rat fibroblasts is 
constitutively active and internalized (17). In fact, the 
basal activity of the α1d-AR was 2-fold greater than that 
of  the  α1b-AR  and  was  increased  following  the  treat-
ment with the inverse agonist prazosin which caused its 
redistribution from the intracellular compartments to 
the plasma membrane. The constitutive activity of the 
α1d-AR was also observed in physiological systems like 
in aorta and mesenteric arteries where it could inhib-
ited by inverse agonists (18). For the α1a or α1b-AR con-
stitutive activity in physiological systems has not been 
investigated.
Altogether, these findings indicate that there might be 
important differences in the constitutive activity of the 
α1-AR subtypes which could have consequences in their 
signaling and regulatory properties in vivo. Such differ-
ences should be further explored and the elucidation 
of their physiological implications might represent an 
important area of investigation.
Oligomerization of the α1-AR subtypes
Findings  in  the  last  decade  challenged  the  widely 
held view of GPCRs functioning as monomeric units. 
Co-immunoprecipitation of differentially tagged GPCRs 
or functional complementation of pairs of co-expressed 
inactive  receptor  mutants  provided  strong  evidence 
that GPCR oligomers do exist. The widespread use of 
biophysical techniques such as fluorescence resonance 
energy transfer (FRET) or bioluminescence resonance 
energy  transfer  (BRET)  between  GPCRs  carrying  the 
appropriate  pair  of  fluorescent/bioluminescent  labels 
suggested oligomerization of a variety of GPCRs. Each 
technique employed has its own shortcomings: whereas 
co-immunoprecipitation cannot rule out indirect inter-
action, energy transfer techniques can only certify that 
the two partners are in close proximity, not necessar-
ily in immediate contact. However, convergent results 
obtained through independent methods eventually led 
to the widespread acknowledgment of the existence of 
GPCR oligomers (7).412    Susanna Cotecchia
Both homo- and hetero-oligomerization have been 
demonstrated for the three α1-AR subtypes in recom-
binant systems (Table 1) (15,16,19). FRET measurements 
as well as co-immunoprecipitation experiments provided 
evidence that both the α1a and α1b-AR can form homo-
oligomers (19). Oligomerization of the α1b-AR did not 
require the integrity of its C-tail, of two glycophorin motifs 
or of the N-linked glycosylation sites at its N-terminus. 
Constitutively active or non-functional α1b-AR mutants 
displayed the same propensity to oligomerize as the wild-
type receptor, indicating that the activation state of the 
receptor is irrelevant for this process. Receptor oligomeri-
zation was not influenced by the agonist epinephrine or 
by the inverse agonist prazosin. Thus, whether homo-
oligomerization of the α1a or α1b-AR has any functional 
relevance is unknown.
Hetero-oligomers were observed between the α1a and 
the α1b-AR subtypes, but not between the α1b-AR and 
other GPCRs. Interestingly, hetero-oligomerization was 
found to have an impact on receptor endocytosis (19). 
Whereas the α1b-AR undergoes agonist-induced inter-
nalization, the α1a-AR does not. However, when the two 
AR subtypes were co-expressed forming heterodimers, 
the endocytosis of each monomer could be triggered 
by stimulation of the other. Colocalization of the two 
monomers could be seen in endocytic vesicles suggesting 
that the α1a/α1b dimers remained stable throughout the 
endocytosis process.
An important effect of hetero-oligomerization has been 
reported for the α1d-AR subytpe. In fact, co-expression of 
the α1dAR with the α1bAR (15) or the β2AR (19) was able 
to rescue surface expression of the α1d-AR, the majority 
of which is intracellular when expressed alone in various 
cell lines. Interestingly, the interaction with the α1b-AR 
modified the pharmacological profile of the α1d-AR which 
looses its affinity for its selective ligand BMY7378 when it 
is co-expressed with the α1b-AR. The α1b/α1d dimer behaves 
as a single functional entity with increased response to 
norepinephrine relative to either monomer alone. The 
α1d-AR receptor was long supposed to be little expressed 
in the heart, as its selective ligand BMY7378 could detect 
only minimal levels of the receptor. However, these find-
ings should be considered in a new light, given that the 
α1b and α1d-AR subtypes co-exist in various tissues and the 
pharmacological profile of the α1d-AR might be different 
than expected because of oligomerization.
Oligomerization of α1-AR subytpes in physiological 
systems has not been explored so far for lack of appro-
priate experimental tools. Therefore, the functional rel-
evance of α1-AR oligomerization in vivo remains elusive. 
However, oligomerization might represent an additional 
mechanism regulating the physiological responses medi-
ated by the α1-AR subytpes which are often co-expressed 
in the same cells. Further exploring the functional cor-
relates  of  receptor  oligomerization  and  assessing  if  it 
occurs in physiological systems might provide interesting 
information about cross-talk effects at the level of α1-AR 
signaling or regulation.
Signaling pathways of the α1-AR subytpes
It has become increasingly evident that the variety of 
functional effects mediated by the α1-ARs in different 
organs must imply the activation of multiple signaling 
pathways beyond activation of PLC via Gq/11. Therefore, 
several studies have attempted to investigate whether 
each α1-AR subtype may activate distinct signaling path-
ways, but our knowledge on this issue is still limited.
It has been reported that stimulation of the α1b and 
α1d-AR can result in the activation of phospholipase A2 in 
COS-1 cells (20); the α1a-AR was not explored. In NIH3T3 
cells, the activation of the α1a and α1b-AR, but not that of 
the α1d, resulted in the stimulation of p21-ras, PI3-kinase 
and  mitogen-activated  protein  kinase  (MAPK)  (21). 
However, the steps leading to the activation of these path-
ways seem to differ between the two receptor subtypes.
In hepatocyte derived cells, stimulation of the α1b-AR 
subtype  inhibits  interleukin  6  signaling  by  a  MAPK 
mechanism (22). An interesting microarray study indi-
cated that the α1-AR subtypes expressed in Rat fibroblasts 
have a differential effect on cell cycle genes with the α1b 
mediating cell-cycle progression, and the α1a and α1d-AR 
mediating G1-S cell cycle arrest (23).
Most of the work investigating α1-AR signaling has 
been  performed  in  cardiomyocytes.  In  fact,  hearts  of 
most  species  express  both  α1a  and  α1b-AR  at  protein 
level whereas the expression of α1d-AR is very low. The 
α1a-AR predominates in humans, whereas the α1b-AR in 
rodents. Some seminal studies (24,25) demonstrated that 
stimulation of the α1-ARs in cardiomyocytes induces a 
hypertrophic response accompanied by the activation 
of early genes (c-fos, c-jun, egr-1) upreagulation of con-
tractile proteins (myosin light chain-2) and reactivation 
of  embryonic  genes  (atrial  natriuretic  factor  (ANF), 
β-myosin heavy chain, skeletal α-actin).
Various  studies  provided  clear  evidence  for  the 
  involvement of both the PLC–MAPK pathway (26) and 
Table 1.  Oligomerization of the α1-adrenergic receptor subtypes.
Receptors Trafficking Pharmacology Signaling Ref.
α1a/α1b Co-endocytosis No change — 19
α1b/α1d ↑ α1d Surface 
expression
↓ α1d Affinity for 
selective ligands
↑ Signaling 15
α1d/β2 ↑ α1d Surface 
expression 
co-endocytosis
— — 16
Homo-
oligomers 
α1a, α1b, α1d
— — — 15,19The α1-adrenergic receptors    413
Rho-signaling (27) in the α1-AR-induced hypertrophic 
response in cardiomyocytes. A recent study supports 
these  earlier  findings  suggesting  that  α1-AR-induced 
cardiac hypertrophy is mediated by three parallel path-
ways:  G12/13-Rho-JNK,  Gq-JNK  (Rho-independent) 
and Gβγ (JNK independent) (28). Recent findings have 
demonstrated that the α1-ARs endogenously expressed 
in rat neonatal cardiomocytes promote RhoA-activation 
via a mechanism that requires G12 and the Rho-guanine 
nucleotide exchange factor AKAP-Lbc and this pathway 
mediates hypertrophy (29).
The respective role in stimulating cardiac hypertro-
phy of the two α1-AR subtypes expressed in heart, the 
α1a and α1b-AR, does not emerge clearly from the in 
vitro studies published so far probably because of the 
limited selectivity of the pharmacological tools avail-
able. In one study on rat neonatal cardiomyocytes, a 
constitutively active form of the α1a-AR activated gene 
expression of the ANF, whereas the analogous consti-
tutively active mutant of the α1b-AR stimulated gene 
expression  of  c-fos,  but  not  of  ANF  (14).  However, 
these  findings  are  intriguing  considering  that  other 
studies reported the opposite and that overexpression 
of the α1b-AR in transgenic mice resulted in a marked 
increase in ANF (see below). In the future, it would 
be   interesting to carry on a systematic investigation 
of different signaling pathways comparing the α1-AR 
subtypes expressed in the same cellular systems and to 
correlate these findings with the growing information 
provided by in vivo studies on genetically modified 
mice (see below).
Regulatory mechanisms and βarrestin 
interaction at the α1-AR subytpes
The α1-AR subtypes display quite divergent regulatory 
properties. In fact, the α1b-AR in recombinant systems 
undergoes  rapid  phospohorylation,  desensitization 
and endocytosis upon exposure to the agonist (30–32). 
Desensitization involves phosphorylation of residues in 
the C-tail of the receptor mediated by G protein-coupled 
receptor  kinases  (GRKs)  (31).  The  endocytosis  of  the 
α1b-AR occurs via clathrin-coated vesicles and seems to 
involve βarrestins (32).
In contrast, the α1a-AR expressed in rat-1 fibroblasts 
is poorly phosphorylated and desensitized compared to 
the α1b-AR (33). In addition, it undergoes very modest 
agonist-induced endocytosis (32).
Fewer  studies  have  investigated  the  desensitiza-
tion of the α1d-AR probably because of its poor expres-
sion in recombinant systems. It has been reported that 
  noradrenaline and direct activation of protein kinase C 
induce phosphorylation of the α1d-AR and this corre-
lates with desensitization of the receptor (34). However, 
desensitization of the α1d-AR was not compared with that 
of the other two subtypes in this study.
Overall, the impact of α1-AR desensitization in physi-
ological systems where the receptors are endogenously 
expressed has been poorly investigated, as it is the case 
for most GPCRs. Therefore, what is the impact of different 
regulatory properties of the α1-AR subtypes on complex 
functions like vasoconstriction, metabolic response, and 
others, is unknown.
Interestingly, the different regulatory features of the 
α1a and α1b-AR seem to correlate with their pattern of 
interaction with βarrestins. In fact, the results from both 
co-immunoprecipitation  experiments  and  βarrestin 
translocation assays indicated that the agonist-induced 
interaction  of  the  α1a-AR  with  βarrestin  was  much 
weaker than that of the α1b-AR (32). The interaction of 
βarrestin with the α1d-AR has not been directly explored 
so far.
These  differences  in  receptor/βarrestin  interaction 
might  have  broader  implications  in  α1-AR  mediated 
signaling because of the well established role played by 
βarrestins in coordinating a variety of signaling networks 
(35). In particular, it is well established that βarrestins 
are scaffolds for components of the MAPK cascade thus 
mediating MAPK activation induced by various GPCRs. 
Investigation of βarrestin-mediated signaling at the α1-AR 
subtypes is an interesting area of investigation which 
has been poorly explored so far and might represent 
one of the mechanisms contributing to the variety of the 
receptor-mediated-responses.
Proteins interacting with different α1-AR 
subtypes
One of the most recent paradigms is that GPCRs can bind 
a variety of proteins and this can promote multiple sig-
naling events which results in growing complexity of the 
receptor-mediated cellular effects (8)
A number of approaches have been followed to iden-
tify novel proteins interacting with the α1-ARs, including 
yeast two-hybrid screen using cytosolic portions of the 
receptors as bait, pull-down or in vitro overlay assays 
using  purified  proteins,  co-immunoprecipitation  of 
receptor-protein complexes from recombinant or native 
cells,  FRET  or  BRET  technology  in  cells.  These  stud-
ies resulted in the identification of a variety of proteins 
interacting with the α1-AR subtypes, several of them in a 
receptor subtype selective pattern (Table 2).
The α1a-AR subtype contains a PDZ binding sequence 
G-E-E-V at its C-terminus that can be expected to give rise 
to PDZ-domain mediated interactions. An early report, at 
the issue of a yeast two-hybrid screen, identified the type 
III PDZ domain of nNOS (neuronal nitric oxide synthase) 
as a potential α1a-AR interacting protein (36) However, 414    Susanna Cotecchia
co-immunoprecipitation studies, while confirming this 
interaction, failed to highlight selectivity for the α1a-AR 
subtype since all three α1-AR subtypes could be co-im-
munoprecipitated with nNOS and this even when they 
were lacking their C-terminus. This interaction appeared 
to be without apparent physiological implications in spite 
of the known role of NO in the regulation of blood pres-
sure and of nNOS as local metabolic inhibitor of α1-AR 
-mediated vasoconstriction.
Another  study  reported  that  the  CUB5  domain  of 
mammalian tolloid (mTLD), a zinc-finger matrix metal-
loprotease of the astacin family, interacted with α1a-AR 
C-tail in a yeast two hybrid screen (37). Overexpression 
of mTLD reduced the number of cell surface receptors 
without affecting total receptor level or affinity when 
transiently expressed in HEK293 cells. No mechanism 
was proposed to account for the observed phenomena.
Interesting prospects were opened by the report of the 
direct interaction between RGS2 (regulator of G protein 
signaling 2) and the third intracellular loop of the α1a-AR 
(38). RGS proteins are well characterized inhibitors of het-
erotrimeric G protein function, acting as GAPs (GTPase 
activating proteins) to increase the rate of GTP hydrolysis 
at Gα subunits and thus terminate signaling. More than 
30 RGS proteins have been identified so far, but many RGS 
proteins can non-selectively bind to and inhibit Gαi/o and 
Gαq11 in reconstituted systems, suggesting that other fac-
tors may regulate their specificity for a particular signaling 
pathway. RGS2 was found to interact with the α1a-AR third 
intracellular loop confirming what previously shown for 
other Gq-coupled receptors, namely the cholinergic mus-
carinic M1, M3, and M5 receptors (39) and it inhibited 
agonist-induced inositol phosphate responses without 
affecting ligand binding.
Two main interacting partners were pulled out of a 
yeast two-hybrid screen for the α1b-AR: the µ2 (or AP50) 
subunit of the clathrin adaptor complex AP2 (40) and 
ezrin,  a  member  of  the  ezrin-radixin-moesin  (ERM) 
protein  family  (41).  The  AP2  complex  is  part  of  the 
endocytic  machinery  mediating  clathrin-dependent 
endocytosis of membrane proteins and it is recruited 
to  agonist-activated  GPCRs  through  the  intermission 
of βarrestins. Binding of AP50 relied on a basic stretch 
of eight arginines in the proximal C-tail of the receptor. 
Direct association of the α1b-AR to AP50 contributed to 
the agonist-induced internalization of the receptor as 
demonstrated by the fact that a receptor mutant lacking 
the AP50 binding motif was delayed in internalization. 
The presence of the eight arginine motif in the C-tail of 
a GPCR is not common, which rules out the hypothesis 
that direct AP50 interaction is a common mechanism 
for  clathrin-mediated  endocytosis.  Interestingly,  this 
feature is shared by the α1d-AR, which contains a stretch 
of seven positive charges in its C-tail, but no studies were 
  undertaken using this receptor subytpe.
In  addition  to  AP50,  the  same  yeast  two-hybrid 
screen  identified  ezrin  as  a  potentially  direct  bind-
ing partner of the α1b-AR (41).  Ezrin  belongs  to  the 
ERM family of proteins, primarily described as link-
ers  between  membrane  proteins  and  cortical  actin. 
Ezrin interactions with polytopic membrane proteins 
generally occur through the adaptor proteins EBP50 
(NHERF1) and E3KARP (NHERF2). So far, a role for 
the  ERM  proteins  in  GPCR  trafficking  was  inferred 
from the finding that NHERF1 binding to some GPCRs 
promoted  their  recycling,  depending  on  its  bind-
ing to ERM proteins. The α1b-AR is the first GPCR for 
which a direct interaction with ezrin has been found. 
Disruption of this interaction by overexpression of a 
dominant negative mutant of ezrin inhibited receptor 
reycling after internalization, as did actin depolymeri-
zation. However, ezrin was also shown to be involved 
in  the  remodelling  of  the  actin  cytoskeleton,  in  the 
modulation of Rho-signaling (by binding to Rho-GTP 
dissociation inhibitor and thourgh direct association 
to several Rho-GTP/GDP exchange factors) as well as 
in anchoring of protein kinase A. Therefore, it would 
be interesting to test whether ezrin is also involved in 
ρ-signaling   mediated by the α1b-AR.
Another  protein,  the  receptor  for  globular  “Heads” 
of c1q (gC1qR), was reported to interact with the same 
arginine-rich sequence in the α1b and the α1d-AR (42). 
gC1qR is a glycoprotein mainly displaying intracellular 
localization, but also present on the surface of macro-
phages and T cells through anchoring to β-integrin, where 
it is part of a complement receptor. No functional relevance 
was demonstrated for its interaction with the α1-ARs.
An interesting protein found to interact with the α1b-AR 
is spinophilin which interacts with other GPCRs, includ-
ing the α2-AR, as well as with the N-terminal domain of 
RGS proteins (RGS1, 2, 4, and 16) which participates in 
GPCR recognition (43). Thus spinophilin might represent 
an interesting functional bridge between RGS and α1AR 
subtypes that don’t bind RGS, like the α1bAR. In fact, it has 
been found that spinophilin increases the RGS2-induced 
Table  2.  Proteins  interacting  with  the  α1-adrenergic  receptor 
subtypes.
Receptor Partner Binding site Functional role Ref.
α1a α1b α1d nNOS Unknown Unknown 36
α1a Tolloid C-tail ↓ Surface expression 37
α1a RGS2 i3 loop(K219-
S220-R238)
↓ Gq signaling 38
α1b AP50 C-tail (8 Arg) ↑ Endocytosis 40
α1b Ezrin C-tail (8 Arg) ↑ Recycling 41
α1b Spinophilin i3 loop ↓ Ca2+ signaling 
induced by RGS2
43
α1d Syntrophins C-term (ETDI) Stabilization of 
  receptor at cell surface
44
α1b α1d gC1qR C-tail (Arg) Unknown 42The α1-adrenergic receptors    415
inhibition of the α1b-AR calcium response. These data 
offer a glimpse into a potentially more general regulatory 
mechanisms of GPCR function by spinophilin.
The α1d-AR was for a long time a “poor relative” to 
the other α1AR subtypes, the α1A and α1B because poorly 
expressed at the cell surface in heterologous systems, 
probably because of its long N-terminus. This peculiarity 
hampered the investigation of its potential interactions 
with other proteins. Apart from the above mentioned 
interaction with gC1qR, whose functional implications 
are  unknown  (42),  another  interacting  partner  of  the 
α1d-AR was α-syntrophin (44). α-syntrophin, a protein 
containing  one  PDZ  domain  and  two  PH  (pleckstrin 
homology) domains, specifically recognized the C-tail of 
the α1d-AR, but not that of the α1a or α1b, in the yeast two-
hybrid assay. The PDZ domains of syntrophin isoforms α, 
β1, and β2, but not γ1 or γ2, could interact with the α1dAR 
C-tail. The α1d-AR possesses the C-terminal sequence 
E-T-D-I, whose mutation impaired syntrophin binding 
to the receptor and markedly decreased norepinephrine-
induced inositol phosphate accumulation. This mutation 
also dramatically decreased receptor expression levels. 
Taken altogether these results suggested that syntrophins 
act  to  maintain  the  stability  of  the  α1d-AR  through  a 
  PDZ-mediated interaction.
Altogether these findings indicate a rather complex 
and heterogeneous pattern of receptor/protein interac-
tions whose physiological implications are far from being 
fully elucidated. The direct interaction of α1AR subtypes 
with selected partners identified in recombinant systems 
might result in new mechanisms of receptor signaling and 
regulation. Since these mechanisms might be specific for 
distinct receptors or cell types, the study of these interac-
tions is an interesting approach to better understand the 
functional specificity of the receptors. However, this would 
require a systematic proteomic approach in different tis-
sues expressing the α1AR subtypes as well as good experi-
mental tools to investigate its functional implications.
Insights from genetically modified mice
Recently, mouse lines carrying genetic modifications of the 
α1-AR subtypes have provided interesting information on 
the in vivo functions of the receptors giving some insight 
into the specificity of their role. The α1b-AR knock out (KO) 
mouse was the first model to be created (45) and it was 
characterized  for  a  number  of  functional  parameters. 
The α1bKO mice displayed: (i) decreased blood pressure 
response to phenylephrine with normal resting pressure 
(45); (ii) hyperinsulinemia, insulin resistance and high 
fat diet-induced obesity (46); and (iii) behavioral changes 
including blunted locomotor response to drugs of abuse 
and  markedly  decreased  sensitivity  to  morphine  and 
cocaine (47). Other mice carrying genetic modifications 
of the α1-AR subtypes have been mainly characterized for 
their cardiovascular phenotype (Table 3) thus allowing to 
build a more comprehensive picture of the functional role 
of each receptor in the cardiovascular system.
Both the α1a and α1d-AR KO mice displayed decreased 
resting blood pressure as well as phenylephrine stimu-
lated pressure response (48,49). The fact that the acute 
response to phenylephrine is decreased in all three KO 
mice indicates that the α1a, α1b and α1d-AR all   contribute to 
the regulation of the vascular tone. However, the contribu-
tion of the α1a and α1d-AR subtypes is prominent because 
deletion of either one of the two receptors leads also to 
decreased resting blood pressure. This can be explained 
by the fact that the α1a-AR prevails in distributing arteries 
(mesenteric, renal) (48) and the α1d-AR in large conduct-
ing arteries (aorta and carotid) (49), whereas the expres-
sion of the α1b-AR is minor in all arteries.
Studies on genetically modified mice have also pro-
vided interesting insight into the role of the α1-AR in car-
diac function and hypertrophy. As mentioned above, the 
α1a and α1b-AR subtypes are both expressed in cardiomyo-
cytes with the α1a predominating in humans and the α1b in 
rodents. Transgenic mice overexpressing a constitutively 
active α1b-AR mutant specifically in the heart display car-
diac hypertrophy without any change in blood pressure 
(50). This supports previous evidence that stimulation of 
α1-ARs in cardiomyocytes in vitro leads to a hypertrophic 
response (24). This finding is also consistent with the role 
played by the Gq/PLC pathway in heart as demonstrated 
by the fact that transgenic mice overexpressing a constitu-
tively active Gαq develop cardiac hypertrophy (51).
Interestingly, another transgenic mouse overxepress-
ing a different constitutively active α1b-AR mutant, under 
the  control  of  the  receptor  own  promoter,  displayed 
a  more  complex  phenotype  characterized  by  cardiac 
hypertrophy as well as autonomic failure (52). This con-
firms a direct role of the α1b-AR in cardiac hypertrophy, 
but indicates that broader effects occur when the   receptor 
is generally overexpressed.
Mice overexpressing constitutively active mutant of 
the α1a-AR subtype have not been generated. However, 
the role of the α1a-AR in heart growth in vivo has been 
demonstrated by studies on double KO mice carrying 
deletions of both the α1a and α1b-AR (53) which displayed 
several abnormalities including: (i) reduced growth of 
the heart after birth; (ii) reduced cardiac output; and 
(iii) increased mortality after pressure overload. These 
findings demonstrate that both the α1a and α1b-AR play 
an important role in heart growth after birth and their 
integrity is required to maintain correct heart function.
These  changes  were,  however,  sex  specific  since 
they were observed in males, but not in females. This 
might be explained by the fact that females have a lower 
sympathetic tone and the growth of their hearts is less 
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Cardiac hypertrophy was not observed in transgenic 
mice  with  cardiac-specific  overexpression  of  the  wild 
type α1a or α1b-AR subtype (54,55) despite the fact that 
they displayed increased expression of ANF. This is unlike 
the phenotype of mice overexpressing the constitutively 
active α1b-AR mutant (50). This difference might be due to 
the fact that the signaling of a constitutively active mutant 
is somehow different or has greater efficacy than that of 
the wild-type receptor.
However, transgenic mice overexpressing either the 
α1a or α1b-AR subtype in the heart provided a number of 
novel findings on the functional role of these receptors in 
heart. In fact, in the heart of the α1b-AR transgenic mice 
left ventricular contraction in response to β-agonists was 
depressed (55). Interestingly, it was found that dampen-
ing of β-AR signaling through adenylate cyclase was due 
to activation of a pertussis-sensitive inhibitory G protein. 
This clearly suggests that when overexpressed α1-ARs can 
couple to inhibitory G proteins.
In conclusion, as summarized in Figure 1, studies 
on mice carrying genetic modifications of the α1-AR 
genes have provided evidence that: (a) all three α1-AR 
α1a, α1b,
α1d>α1b
α1a>α1b
heart growth/hypertrophy
inotropy
vasoconstriction of
conducting arteries
(aorta, carotid)
vasoconstriction of
resistance arteries
(renal, mesenteric)
Figure 1.  The α1-adrenergic receptor subtypes in the cardiovascu-
lar system. This figure summarizes the main roles played by distinct 
α1-AR subtypes in the cardiovascular system highlighted by studies on 
genetically modified mice.
Table 3.  Cardiovascular phenotype of mice carrying genetic modifications of different α1-adrenergic receptor subtypes.
Receptor Genetic modification Phenotype Ref.
α1b Gene deletion ↓ Resting blood pressure 
↓ Blood pressure response to phenylephrine
48
α1a Overexpression/heart-specific promoter ↑ Contractile response 
↑ Survival 
↑ ANF mRNA  
No hypertrophy 
↑ Post-ischemic protection
54
α1b Gene deletion Normal resting blood   pressure 
↓ Blood pressure response to phenylephrine 
↓ Vasoconstriction
45
α1b Overexpression/heart-specific promoter ↑ Phospholipase C activity 
↑ ANF mRNA  
No hypertrophy  
↓ Contractile and heart rate response to β-AR
55
CAM α1b Overexpression/heart-specific promoter ↑ Phospholipase C activity  
↑ Hypertrophy  
↑ ANF mRNA  
Normal blood pressure
50
CAM α1b Overexpression/receptor promoter ↓ Contractile response to β-AR 
Autonomic failure  
↑ Hypertrophy
52
α1a α1b Double gene deletion In malesNormal resting blood pressure  
↓ Cardiac growth after birth  
↓ Heart rate, ↓ cardiac output  
↓ Basal ERK activity  
↑ Mortality to pressure overload  
Contraction abnormalities
53
α1d Gene deletion ↓ Resting blood pressure  
↓ Blood pressure response to phenylephrine  
↓ Vasoconstriction
49
α1dα1b Double gene deletion ↓ Resting blood pressure 
↓↓ Blood pressure response to phenylephrine 
↓↓ Vasoconstriction
57The α1-adrenergic receptors    417
subtypes contribute to the regulation of blood   pressure 
with a prominent role for the α1a and α1d; (b) both the 
α1a and α1b-AR play a role in cardiac pathological hyper-
trophy (independent from pressure overload) or physi-
ological hypertrophy associated with postnatal growth; 
and (c) the α1-ARs maintain normal heart function as 
demonstrated by the fact that the double deletion of 
the α1a and α1b-AR results in some features of failing 
heart.
Other interesting features of the α1-AR subtypes have 
emerged from studies on the genetically modified mice 
including  their  effects  on  heart  contractile  function, 
cardiac  rhythm  and  protection  from  ischemic  injury 
(56). Additional studies are required to gain a deeper 
  understanding of these complex effects.
Conclusions and perspectives
In the past years, we have gained significant information 
of some molecular properties and functional implica-
tions of the α1-AR subtypes both from in vitro and in vivo 
studies.
Several studies focused on individual receptor sub-
types whereas only few others attempted to compare the 
behavior of different receptors in similar experimental 
conditions. This latter approach should be implemented 
in future studies, both in vitro and in vivo, to better assess 
differences  and  similarities  among  the  three  α1-AR 
subtypes.
The  elucidation  of  receptor-mediated  signaling 
events in time and space will depend on a much deeper 
understanding of the interactions among receptors and 
signaling molecules which has recently emerged as an 
important paradigm in the GPCR field. Beyond receptor 
oligomerization (Table 1), a number of novel proteins 
have been found to interact with the α1-AR subtypes 
(Table 2), but for most of these interactions the functional 
implications are elusive. The vast majority of studies on 
α1-AR subtypes have been performed in recombinant 
systems. A big challenge in the future will be to explore 
the functional implications of a variety of interactions in 
different tissues and physiological conditions. The α1-AR 
subtypes are important regulators of several physiologi-
cal parameters as highlighted by studies in genetically 
modified mice (Table 3), and further investigation on this 
receptor system might have new interesting implications 
in pharmacology and drug development.
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